Diabetes

ePharma: Novo Nordisk's lessons from a diabetes education campaign

ePharma: Novo Nordisk's lessons from a diabetes education campaign

By

Why the drugmaker's partnership with a YouTube star is still getting hits.

Virta Health CEO Sami Inkinen on changing patient behavior: 'We're cutting down trees in the wrong forest'

Virta Health CEO Sami Inkinen on changing patient behavior: 'We're cutting down trees in the wrong forest'

By

Seven questions for the Virta Health chief executive and cofounder of Trulia.

Five things for pharma marketers to know: Wednesday, January 10, 2018

Five things for pharma marketers to know: Wednesday, January 10, 2018

By

Maker of Botox biosimilar Evolus files IPO; pharma execs expect major acquisitions in 2018; J&J and Bayer win Xarelto reversal verdict

Five things for pharma marketers to know: Friday, January 5, 2018

Five things for pharma marketers to know: Friday, January 5, 2018

By

Takeda announces deals worth more than $1 billion; biotech and pharma investments reached $10.5 billion in 2017; prescriptions for nerve pain on the rise

Five things for pharma marketers to know: Thursday, December 21, 2017

Five things for pharma marketers to know: Thursday, December 21, 2017

By

BI to pay $13.5 million for misleading marketing; ICER: CAR-T therapies more cost-effective than chemotherapy; FDA approves Roche's breast cancer combo therapy

Five things for pharma marketers to know: Thursday, December 14, 2017

Five things for pharma marketers to know: Thursday, December 14, 2017

By

Pharma R&D return on investment falls to eight-year low; FDA approves Pfizer's biosimilar to J&J's Remicade; Novartis to downsize generics business

Five things for pharma marketers to know: Tuesday, December 12, 2017

Five things for pharma marketers to know: Tuesday, December 12, 2017

By

FDA issues prescription drug promotion guidance; FDA approves first follow-on biologic of Lilly's Humalog; drugmakers allegedly hired nurses to promote drugs

Five things for pharma marketers to know: Monday, December 11, 2017

Five things for pharma marketers to know: Monday, December 11, 2017

By

Pfizer's Viagra generic to sell for half the price; GSK seeks oncology deals; Ionis' experimental Huntington's drug tackles toxic protein for the first time

Lighthouse wins grand prize for voice-activated diabetes app at Hitlab

Lighthouse wins grand prize for voice-activated diabetes app at Hitlab

By

Lighthouse received $50,000 for application aimed at providing more accessible and engaging care for those living with diabetes.

Five things for pharma marketers to know: Wednesday, December 6, 2017

Five things for pharma marketers to know: Wednesday, December 6, 2017

By

FDA approves Novo's diabetes drug; Walgreens undergoes rebranding in the wake of CVS-Aetna merger; pharma increasingly transparent about clinical trial data

Drugmakers and celebrities partner to raise diabetes awareness

Drugmakers and celebrities partner to raise diabetes awareness

By

Celebrities such as Angela Bassett and Mike Golic share their personal experiences about diabetes.

Five things for pharma marketers to know: Monday, November 13, 2017

Five things for pharma marketers to know: Monday, November 13, 2017

By

Dynavax receives FDA approval for hepatitis-B vaccine; Novartis strikes R&D deal with gene-editing startup; White House nominates new HHS head

Novo's experimental diabetes drug likely to compete with Trulicity

Novo's experimental diabetes drug likely to compete with Trulicity

By

An FDA advisory committee is scheduled to vote Wednesday on whether to approve Novo's semaglutide, which, if approved, could steal market share from Eli Lilly's Trulicity.

Five things for pharma marketers to know: Friday, August 25, 2017

Five things for pharma marketers to know: Friday, August 25, 2017

By

Google surveys for depression; patients with diabetes that adhere to their regimen had fewer ER visits; Biogen, Samsung scores Humira biosimilar approval in EU

Diabetes drugs must prove their value to payers, analysts say

Diabetes drugs must prove their value to payers, analysts say

By

CVS Health's decision to remove Lilly's Jardiance for J&J's Invokana has analysts wondering if exclusive pricing contracts could shape the future of the GLP-1 class.

Johnson & Johnson is big winner in CVS diabetes formulary changes

Johnson & Johnson is big winner in CVS diabetes formulary changes

By

CVS Health will remove Lilly's Jardiance in favor of J&J's Invokana.

Five things for pharma marketers to know: Thursday, July 27, 2017

Five things for pharma marketers to know: Thursday, July 27, 2017

By

Generic drugmakers reportedly seeking deals; GSK to refocus R&D; Merck and AstraZeneca to test combo cancer drug

Five things for pharma marketers to know: Thursday, July 20, 2017

Five things for pharma marketers to know: Thursday, July 20, 2017

By

About 4.4 billion prescriptions filled in the U.S. in 2016; Sanofi and Ablynx reach I-O deal; biotech M&A slows in H1

Diabetes drugmakers partner with mobile startups to boost patient engagement

Diabetes drugmakers partner with mobile startups to boost patient engagement

By

Novo Nordisk and Roche are two examples of drugmakers that are turning to digital-health startups to better engage with patients and mine valuable real-world evidence.

Five things for pharma marketers to know: Thursday, July 13, 2017

Five things for pharma marketers to know: Thursday, July 13, 2017

By

AstraZeneca CEO reportedly moving to Teva; the FDA reverses on approval for Amicus drug; Merck names winners of Alexa challenge

Five things for pharma marketers to know: Wednesday, July 5, 2017

Five things for pharma marketers to know: Wednesday, July 5, 2017

By

Amgen and Teva raise prices of leukemia drugs twice this year; Roche acquires diabetes app; docs use Snapchat to share patient scans

For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive

For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive

By

Under siege from intense competition and the rise of value-based contracts, diabetes drugmakers look to outcomes data to stand out.

Five things for pharma marketers to know: Friday, June 9, 2017

Five things for pharma marketers to know: Friday, June 9, 2017

By

The FDA asks Endo to take opioid off the market; Lilly partners with Swiss biotech; House committee advances PDUFA bill — without off-label provision

J&J blames lower Xarelto and Invokana sales on payer pressure

J&J blames lower Xarelto and Invokana sales on payer pressure

By

The drugmaker said it has been forced to provide higher rebates to PBMs and insurers for certain drugs.

Five things for pharma marketers to know: Thursday, April 13, 2017

Five things for pharma marketers to know: Thursday, April 13, 2017

By

Biogen licenses experimental Alzheimer's drug; Apple reportedly working on diabetes sensors; doc warns against industry payments

Five things for pharma marketers to know: Friday, April 7, 2017

Five things for pharma marketers to know: Friday, April 7, 2017

By

The FDA rejected an outcomes update to the Januvia label; digital-health funding dropped in Q1 of 2017; the FDA approves 23andMe's genetic test

Rick Altinger, Glooko

Rick Altinger, Glooko

Rick Altinger is CEO of Glooko.

Sean Duffy, Omada Health

Sean Duffy, Omada Health

Sean Duffy is CEO of Omada Health.

Five things for pharma marketers to know: Monday, March 20, 2017

Five things for pharma marketers to know: Monday, March 20, 2017

By

Study finds SGLT-2 inhibitors lowered risk of death; former FDA commissioners raise drug importation issues; Bayer, J&J's Xarelto lowered VTE risk in study

Five things for pharma marketers to know: Tuesday, February 21, 2017

Five things for pharma marketers to know: Tuesday, February 21, 2017

By By

Pharma industry remains focused on Alzheimer's, despite setbacks; few new diabetes drugs in development; the FDA issues complete response letter to Trevena